Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine

Chinese Medicine

Albert J Allen⁵  Rodrigo Escobar¹  Jody Arsenault⁴  Yoko Tanaka⁵  David Williams⁴  Alexandra Kutzelnigg³  Miguel Casas²  Lenard A Adler⁶  Himanshu Upadhyaya⁵ 

[1] Lilly Research Laboratories, Sannomiya Plaza Bldg. 7-1-5, Isogami Dori, Chuo-ku, Kobe, 651-0086, Japan;Servicio de Psiquiatria, Hospital Universitari Vall d'Hebron, Universidad Autonoma de Barcelona, Passeig Vall d'Hebron, 119-129, Barcelona, 08035, Spain;Universitätsklinik für Psychiatrie und Psychotherapie, Abteilung für Biologische Psychiatrie, Medizinische Universität Wien, Währinger Gürtel 18-20, Wien, 1090, Austria;PharmaNet/i3, an inVentiv Health Company, Indianapolis, IN, 46280, USA;Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA;New York University School of Medicine, New York University Medical Center and NY VA Harbor Healthcare Service, 650 First Ave., 7th Floor, New York, NY, 10016, USA

关键词: Atomoxetine;    European;    Adult;    Attention deficit/hyperactivity disorder;   

Others  :  790984
DOI  :  10.1186/1753-2000-7-14

 received in 2012-07-18, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

Background

Attention deficit/hyperactivity disorder (ADHD) often presents as an impairing lifelong condition in adults; yet it is currently underdiagnosed and undertreated in many European countries. This analysis examines the characteristics of adult patients with ADHD in a European (EUR) and non-European (NE) patient population.

Methods

Baseline data from the open-label treatment period of a randomized trial of atomoxetine in adult patients with ADHD (N=2017; EUR, n=1217; NE, n=800) were examined. All patients who were enrolled were included in the baseline analyses.

Results

The demographics for patients in the EUR and NE groups were comparable. Patients in the EUR group had a somewhat lower percentage of prior exposure to psychostimulants compared with the NE group (32.7% vs. 38.9%, p=.0049). Scores on the Conners’ Adult ADHD Rating Scale-Investigator Rated: Screening Version with adult ADHD prompts (18-item total, inattentive and hyperactive/impulsive subscales, and index) were comparable. The adult ADHD Quality of Life-Life Outlook and Life Productivity domain scores were significantly different between groups (p≤.0004). The EuroQol-5 Dimension United Kingdom and United States population-based index scores and Health State score were comparable between groups.

Conclusions

Adults with ADHD in Europe present similar demographics and baseline characteristics to those outside Europe and hence, study results outside Europe may be generalizable to patients in Europe.

Trial registration

Clinicaltrials.gov, NCT00700427

【 授权许可】

   
2013 Upadhyaya et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Barkley RA, Fischer M, Smallish L, Fletcher K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002, 111:279-289.
• [2]Faraone SV, Biederman J, Mick E: The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006, 36:159-165.
• [3]Gittelman R, Mannuzza S, Shenker R, Bonagura N: Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 1985, 42:937-947.
• [4]Lara C, Fayyad J, de Graaf R, Kessler RC, Aguilar-Gaxiola S, Angermeyer M, Demytteneare K, De Girolamo G, Haro JM, Jin R, Karam EG, Lepine JP, Mora ME, Ormel J, Posada-Villa J, Sampson N: Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the world health organization world mental health survey initiative. Biol Psychiatry 2009, 65:46-54.
• [5]Mannuzza S, Klein RG, Moulton JL 3rd: Persistence of attention-deficit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 2003, 7:93-100.
• [6]Mannuzza S, Klein RG, Addalli KA: Young adult mental status of hyperactive boys and their brothers: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1991, 30:743-751.
• [7]Rasmussen P, Gillberg C: Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000, 39:1424-1431.
• [8]Weiss G, Hechtman L, Milroy T, Perlman T: Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985, 24:211-220.
• [9]Wender PH, Wolf LE, Wasserstein J: Adults with ADHD. An overview. Ann N Y Acad Sci 2001, 931:1-16.
• [10]Fayyad J, de Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lepine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190:402-409.
• [11]Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, Greenhill LL, Jaeger S, Secnik K, Spencer T, Ustun TB, Zaslavsky AM: Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005, 57:1442-1451.
• [12]Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM: The prevalence and correlates of adult adhd in the united states: results from the national comorbidity survey replication. Am J Psychiatry 2006, 163:716-723.
• [13]Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP: Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 2005, 35:817-827.
• [14]Simon V, Czobor P, Bálint S, Mészáros A, Bitter I: Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194:204-211.
• [15]Faraone SV, Sergeant J, Gillberg C, Biederman J: The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003, 2:104-113.
• [16]Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P: European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010, 10:67. BioMed Central Full Text
• [17]Barkley RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63(Suppl 12):10-15.
• [18]Wilens TE, Dodson W: A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004, 65:1301-1313.
• [19]McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC: Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009, 194:273-277.
• [20]Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A: Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993, 150:1792-1798.
• [21]Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology: Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007, 21:10-41.
• [22]Conners CK, Erhardt D, Sparrow E: Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems Inc; 1999.
• [23]Adler LA, Cohen J: Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004, 27:187-201.
• [24]Guy W: ECDEU Assessment Manual For Psychopharmacology, Revised. US Department of Health, Education, and Welfare: Bethesda, MD; 1976.
• [25]Adler LA, Spencer T, Faraone SV, Reimherr FW, Kelsey D, Michelson D, Biederman J: Training raters to assess adult ADHD: reliability of ratings. J Atten Disord 2005, 8:121-126.
• [26]Cohen J: A power primer. Psychol Bull 1992, 112:155-159.
• [27]Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41:582-592.
• [28]Pickard AS, Neary MP, Cella D: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5:70. BioMed Central Full Text
• [29]Faraone SV, Mick E: Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010, 33:159-180.
• [30]Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D: Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009, 29:44-50.
• [31]Durell T, Adler L, Wilens T, Paczkowski M, Schuh K: Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord 2010, 13:401-406.
• [32]Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53:112-120.
• [33]National Institute for Health and Clinical Excellence: Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. 2008. Available from http://guidance.nice.org.uk/CG72 webcite
• [34]Buitelaar JK, Barton J, Danckaerts M, Friedrichs E, Gillberg C, Hazell PL, Hellemans H, Johnson M, Kalverdijk LJ, Masi G, Michelson D, Revol O, Sebastian JS, Zhang S, Zuddas A: A comparison of North American versus non-North American ADHD study populations. Eur Child Adolesc Psychiatry 2006, 15:177-181.
• [35]Preuss U, Ralston SJ, Baldursson G, Falissard B, Lorenzo MJ, Rodrigues Pereira R, Vlasveld L, Coghill D: Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006, 15(Suppl 1):I4-14.
• [36]Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993, 50:565-576.